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Associations between cadmium exposure and
neurocognitive test scores in a cross-sectional
study of US adults
Timothy Ciesielski1*, David C Bellinger2,3,4, Joel Schwartz2, Russ Hauser2 and Robert O Wright5

Abstract
Background: Low-level environmental cadmium exposure and neurotoxicity has not been well studied in adults.
Our goal was to evaluate associations between neurocognitive exam scores and a biomarker of cumulative
cadmium exposure among adults in the Third National Health and Nutrition Examination Survey (NHANES III).
Methods: NHANES III is a nationally representative cross-sectional survey of the U.S. population conducted between
1988 and 1994. We analyzed data from a subset of participants, age 20–59, who participated in a computer-based
neurocognitive evaluation. There were four outcome measures: the Simple Reaction Time Test (SRTT: visual motor
speed), the Symbol Digit Substitution Test (SDST: attention/perception), the Serial Digit Learning Test (SDLT) trialsto-criterion, and the SDLT total-error-score (SDLT-tests: learning recall/short-term memory). We fit
multivariable-adjusted models to estimate associations between urinary cadmium concentrations and test scores.
Results: 5662 participants underwent neurocognitive screening, and 5572 (98%) of these had a urinary cadmium
level available. Prior to multivariable-adjustment, higher urinary cadmium concentration was associated with worse
performance in each of the 4 outcomes. After multivariable-adjustment most of these relationships were not
significant, and age was the most influential variable in reducing the association magnitudes. However among
never-smokers with no known occupational cadmium exposure the relationship between urinary cadmium and
SDST score (attention/perception) was significant: a 1 μg/L increase in urinary cadmium corresponded to a 1.93%
(95%CI: 0.05, 3.81) decrement in performance.
Conclusions: These results suggest that higher cumulative cadmium exposure in adults may be related to subtly
decreased performance in tasks requiring attention and perception, particularly among those adults whose
cadmium exposure is primarily though diet (no smoking or work based cadmium exposure). This association was
observed among exposure levels that have been considered to be without adverse effects and these levels are
common in U.S. adults. Thus further research into the potential neurocognitive effects of cadmium exposure is
warranted. Because cumulative cadmium exposure may mediate some of the effects of age and smoking on
cognition, adjusting for these variables may result in the underestimation of associations with cumulative cadmium
exposure. Prospective studies that include never-smokers and non-occupationally exposed individuals are needed
to clarify these issues.
Keywords: Cadmium, Neurocognitive, Neuropsychological, NES2, NHANES, Attention, Smoking, Metals, Aging,
Cognitive

* Correspondence: timothyhciesielski@gmail.com
1
Institute for Quantitative Biomedical Sciences, Dartmouth College, Geisel
School of Medicine at Dartmouth, Hanover, New Hampshire, USA
Full list of author information is available at the end of the article

© 2013 Ciesielski et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Ciesielski et al. Environmental Health 2013, 12:13
http://www.ehjournal.net/content/12/1/13

Background
Cadmium is a heavy metal found in food, tobacco smoke,
and certain occupational environments [1]. In adults,
elevated cadmium exposure has been linked to a variety of
neuropsychological deficiencies such as: reading difficulties,
behavioral problems [2], poor visual-motor performance,
complaints of decreased concentration [3], reduced attention, psychomotor speed, and memory [4] as well as lower
cognitive scores among elderly adults with [5] or without
concomitantly elevated zinc exposure [6]. In contrast,
Nordberg et al. [7] found no association between blood cadmium and neurocognitive test scores in elderly adults. Three
of these studies were done in occupational settings with
small sample sizes, and the three larger studies only evaluated elderly adults. Thus there is a need for populationbased studies of younger adults. In this study we analyzed a
large representative sample of US adults ages 20–59, from
the Third National Health and Nutrition Examination Survey (NHANES III) to determine if higher levels of urinary
cadmium were associated with poorer performance in
several tests from the Neurobehavioral Evaluation System 2
(NES2), a computer-based neurocognitive assessment [8,9].
In prior risk assessments kidney damage has been considered the most sensitive endpoint of cadmium toxicity
and reference levels for urinary cadmium have been established to protect against this effect (EFSA 2009: 1 μg Cd/g
creatinine, WHO/FAO 2011: 5.24 μg Cd/g creatinine)
[1,10]. We compare our results to these reference levels to
determine if any associations with adverse neurocognitive
outcomes are present at exposure levels below these
current thresholds of concern.
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estimate cumulative cadmium exposure [16]. We used
urinary cadmium concentration assessed via atomic absorption spectrophotometry (AAS) with Zeeman background correction as the exposure metric for these analyses
[17,18]. Because these were spot urine samples we included
urinary creatinine concentration as an independent covariate in our models in order to account for individual
variation in fluid intake/urine dilution [19].
Covariates

NHANES III is a cross sectional survey of a representative sample of the United States population conducted
between 1988 and 1994. It includes questionnaire data,
medical examination data, and laboratory data from biological specimens [11,12]. Urinary cadmium information
is publicly available for participants over 6 years of age,
and neuropsychological screening was done on a random subsample of participants (n = 5662) between age
20 and 59 [13,14]. Additional information for NHANES
III based analyses is available online: www.cdc.gov/nchs/
nhanes/nh3data.htm [11]. The NHANES website (http://
www.cdc.gov/nchs/nhanes/irba98.htm) notes that documented consent was obtained from participants and
approval was obtained from the NHANES Institutional
Review Board (its name changed to NCHS Research
Ethics Review Board in 2003) [15].

Information on a number of potentially relevant covariates was available [11]. The covariates included in
our multivariable-adjusted regression models were urinary
creatinine (mg/dL), age (in years), sex, race-ethnicity (nonHispanic white, non-Hispanic black, Mexican American,
and other), smoking status (never, former, or current
smoker), serum cotinine (μg/L), blood lead (μg/dL), language the exam was given in (Spanish or English), education (in years), and poverty income ratio (PIR - family
income divided by the poverty threshold).
As discussed above, we included the independent variable for urinary creatinine in our models to control for
differences in urine flow rate. This is a preferred method
for avoiding potential biases related to differences in free
water intake/urine dilution in epidemiologic studies that
utilize urinary biomarkers of exposure [19]. The remainder of the variables in the models are known predictors
of neurocognitive outcome [20-25], that 1) appear to
have a relationship with cadmium exposure (data not
shown) and 2) are not likely to be on the causal pathway
between cadmium exposure and neurocognitive outcome. Thus we included them in the models to adjust
for potential confounding. Note that there was not much
difference between the urinary cadmium levels of males
and females, consequently any potential confounding by
this variable should be relatively small. However, the
inclusion of this variable was crucial for the interaction
analyses. There is evidence that cadmium may mimic
sex hormones, and have different toxicokinetics in males
and females [26], thus it was important to evaluate if the
relationships between urine cadmium and the outcomes
differed by sex.
Occupational information was available and was used
to identify a subpopulation of never smokers who had
no evidence of occupational cadmium exposure (details
in the statistical analysis section). The secondary analyses in this subpopulation allowed us to evaluate associations with cadmium in the absence of potential
confounding from unmeasured co-exposures present in
tobacco smoke and certain work environments.

Exposure assessment

Outcome measures

Cadmium accumulates in the kidney, and urinary cadmium concentration is considered a useful biomarker to

Neuropsychological performance was assessed with three
subtests from the Neurobehavioral Evaluation System 2

Methods
Data source and study population
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(NES2), which is a computer-based screening program
designed for epidemiologic studies [8]. Details on the use
of NES2 in NHANES III have been previously published
[21,27]. The first subtest was the Simple Reaction Time
Test (SRTT). This subtest quantifies visual motor speed,
and involves pushing a button when a specific shape
appears on the screen. The second subtest was the Symbol
Digit Substitution Test (SDST), which is a measure of
attention and perception. In this subtest 9 digits are paired
with 9 symbols in a grid, and the subject matches the correct digits with symbols on a second grid. The third subtest, the Serial Digit Learning Test (SDLT), is a measure of
learning recall and short-term memory. Strings of 8 numbers are presented on the screen. The participant must
then remember and enter the 8 digits. There are two summary measures for this subtest. The first summary measure is the number of trials required to meet the criterion.
Criterion consists of doing the task correctly twice in a
row (top coded at 8 trials max). Error scores are given for
each trial (0 = 8 digits correct, 1 = 6–7 digits correct, and
2 = less than 6 digits correct) [13], and the second summary measure is the sum of these error scores. For each of
these four outcome measures, lower scores correspond to
better performance.
Statistical analysis

For the SRTT and SDST analyses we used the GAMM
function in R version 2.10.1 (The R Foundation for Statistical Computing, http://www.r-project.org/) to build
mixed effect regression models. This approach accounts
for clustering related to the hierarchical sampling structure of NHANES III by using a random intercept for
each study location [28,29]. We specified weight variables in GAMM to appropriately account for unequal
probabilities of selection created by the intentional oversampling of certain segments of the US population [12].
This approach was taken because standard survey statistics packages do not allow the use of penalized splines to
assess nonlinearity. In order to consider potential nonlinear relationships between urine cadmium and an outcome, or a covariate and an outcome, we initially modeled
continuous predictor variables with penalized splines that
were selected via a Generalized Cross Validation (GCV)
procedure. GCV uses an automated iterative selection
process to identify a smooth function which describes the
relationship between two continuous variables [28,30].
The SRTT and SDST outcomes had roughly log normal distributions, and we log transformed these variables for the analyses. We constructed three models for
each outcome. Model 1 included only urinary cadmium
and an independent term for urinary creatinine. Model 2
added age, sex, race-ethnicity, reported smoking status, cotinine, blood lead, the language in which the exam was given
(Spanish, English), education level, and Poverty Income
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Ratio. Model 3 was the same as model 2 except that the
terms for smoking status and cotinine were removed. We
performed this sensitivity analysis (model 3) because
smoking is a source of cadmium exposure [1] and if any
effect of smoking on cognition is mediated by cadmium,
then adjusting for smoking may mask a cadmium effect.
We initially included continuous variables in the models
as splines, but if the GCV process did not provide evidence of non-linearity, we thereafter included this variable
as a linear term. In the multivariable-adjusted SRTT and
SDST models (model 2), GCV did not detect evidence of
non-linearity, suggesting that urinary cadmium could be
modeled as a linear term. For comparison, we modeled
urinary cadmium as a linear term in models 1 and 3 as
well. One participant had a very high urinary cadmium
concentration (14.69 μg/L) that was over 18 standard
deviations (0.77 μg/L) above the mean (0.64 μg/L), and was
excluded from the regression models.
The two SDLT outcomes had discrete right censored
distributions that were not transformable to a normal
distribution. Therefore, we dichotomized these variables
at the median and performed logistic regression analyses. We used proc rlogist in SAS callable SUDAAN
(SAS 9.1.3 and 9.2: SAS Institute Cary, NC; SUDAAN
10.0.1 and 11.0.0: Research Triangle Institute Raleigh,
NC), to build multivariable logistic regression models in
the same manner as with the SRTT and SDST models,
except that splines were not considered. The proc rlogist
command in SUDANN allowed us to specify strata and
primary sampling unit (PSU) variables to account for
clustering related to the hierarchical sampling structure,
and allowed us to specify weight variables to account for
the oversampling of certain groups [12].
In order to determine which variables had the greatest
influence on the urinary cadmium effect estimates in the
multivariable-adjusted models, we re-ran model 2 several times for each of the 4 outcomes, leaving out one
covariate each time. Upon removing the term for age
from the SDST model, there was a convergence problem
that resolved when urinary creatinine was modeled as a
linear term. Therefore we modeled urinary creatinine
with a linear term in the SDST confounding magnitude
analyses. In order to investigate effect modification by
sex, we added a sex-cadmium interaction term to model
2 for each of the four outcomes.
To further differentiate associations with cumulative
cadmium exposure from associations with other aspects
of aging we removed the continuous age variable from
model 2 and added an ordinal age variable with 4 age
categories (20–29, 30–39, 40–49, and 50–59 years). We
then added an interaction term between urinary cadmium and this four category age variable to obtain
stratum specific effect estimates for urinary cadmium
within each of these age categories.
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In order to evaluate associations with urinary cadmium in the absence of potential confounding from
co-exposures in tobacco smoke and certain occupational
environments we also evaluated models 1 and 2 (excluding
the smoking status term) among never smokers who had
no evidence of work-based cadmium exposure. Participants were considered to have potential occupational exposure if they reported a current or long held previous job
in an industry that may involve cadmium exposure (mining, metal industries, chemicals/petroleum/coal products,
rubber/plastics/leather products, electrical machinery/
equipment/supplies) [31]. This resulted in the exclusion of
195 of the 2851 never smokers (6.8%) from these analyses.

Results
A urinary cadmium level was available for 5572 (98%) of
the 5662 NHANES III participants evaluated with the
NES2 exam. Of these, SRTT data were available for 4848
(87%), and SDST data were available for 5021 (90%). For
the SDLT, data on trials-to-criterion were available for
4845 (87%) and data on total-error-score were available
for 4911 (88%). The median urinary cadmium concentration in the study population was 0.42 μg/L and the
interquartile range was 0.19 - 0.82 μg/L (Table 1). Other
characteristics of the study population are summarized
in Table 1. For each of the 4 outcomes, people with

worse scores tended to have higher urinary cadmium
concentrations (Table 2).

Simple reaction time test (SRTT: visual motor speed)

The effect estimate for urinary cadmium in the SRTT
model adjusted only for urinary creatinine (model 1) was
positive and significant (βCd = 0.0161, 95%CI: 0.0087,
0.0235) (Table 3). Due to the log transformation of the
SRTT scores in these models, this effect estimate predicts a 1.61% higher SRTT score with each 1 μg/L increase in urinary Cd (higher scores indicate worse
performance for each of these tests). However, after
adjusting for age, sex, race-ethnicity, smoking status,
cotinine, blood lead, language the exam was given in,
education level, and Poverty Income Ratio (model 2) the
effect estimate was reduced and no longer significant
(βCd = −0.0034, 95%CI: -0.0122, 0.0054). In the sensitivity
analysis which did not adjust for smoking status and
cotinine (model 3), the urinary cadmium term remained
non-significant (βCd = −0.0062, 95%CI: -0.0145, 0.0021).
The terms for age and sex were most responsible for
reducing the urinary cadmium effect estimate (data not
shown). The multivariable-adjusted β for urinary cadmium was 0.0066 (95%CI: -0.0016, 0.0148) when not
adjusting for age, and 0.0058 (95%CI: -0.0029, 0.0144)
when not adjusting for sex.

Table 1 Characteristics of the study populationa
N

(%)

Male

2548

(45.7)

Female

3024

(54.3)

Sex

Race-Ethnicity
Non-Hispanic White

1900

(34.1)

Non-Hispanic Black

1753

(31.5)

Mexican

1685

(30.2)

Other Race

234

(4.2)

4408

(86.6)

Yes

681

(13.4)

Missing

483

Exam Given in Spanish
No

Smoking Status
Never Smoker

N

Median

(IQRb)

Urinary Cadmium (μg/L)

5572

0.42

(0.19 - 0.82)

Urinary Creatinine (mg/dL)

5547

137

(79–197)

Age (in years)

5572

36

(27–45)

Education (in years)

5538

12

(10–14)

Poverty Income Ratio

5152

1.98

(1.02 - 3.36)

Serum Cotinine (μg/L)

5269

0.57

(0.13 - 105)

Blood Lead (μg/dL)

5388

2.8

(1.6 - 4.6)

SRTT

4848

229

(209–255)

5021

2.67

(2.29 - 3.20)

trials-to-criterion

4845

5

(3–8)

total-error-score

4911

4

(2–10)

NES2 Test Scores
2851

(51.2)

Former Smoker

1039

(18.7)

SDST

Current Smoker

1681

(30.2)

SDLT

Missing

1

a
b

study population values, not weighted for oversampling.
interquartile range.
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Table 2 Urinary cadmium concentrations (μg/L) by
neurocognitive test performanceab
N

Median Interquartile range

SRTT (in ms)
visual motor speed

4848 total

158.5 - 209.3 (better)

1211

0.38

0.17 - 0.78

209.3 - 228.6

1213

0.40

0.19 - 0.80

228.6 - 254.6

1212

0.43

0.19 - 0.84

254.6 - 660.1 (worse)

1212

0.44

0.21 - 0.85

Missing

724

0.47

0.22 - 0.85

SDST (in s/correct digit)
attention/perception

5021 total

1.4 - 2.3 (better)

1223

0.31

0.14 - 0.59

2.3 - 2.7

1283

0.42

0.20 - 0.81

2.7 - 3.2

1254

0.45

0.21 - 0.85

3.2 - 22.2 (worse)

1261

0.52

0.22 - 1.03

Missing

551

0.45

0.21 - 0.85

SDLT trials-to-criterion
learning recall/short-term
memory

4845 total

2 (better)

497

0.36

0.16 - 0.74

3–4

1624

0.37

0.17 - 0.72

5–7

1271

0.46

0.22 - 0.82

8 (worse)

1453

0.46

0.21 - 0.93

Missing

727

0.45

0.20 - 0.87

SDLT total-error-score
learning recall/short-term
memory

4911 total

0 - 1 (better)

982

0.34

0.16 - 0.71

2–3

1066

0.38

0.18 - 0.68

4–9

1565

0.47

0.22 - 0.85

10 - 16 (worse)

1298

0.47

0.21 - 0.94

Missing

661

0.45

0.20 - 0.86

(βCd = 0.0068, 95%CI: -0.0028, 0.0164). However, in the
sensitivity analysis, which did not adjust for smoking status or cotinine, the urinary cadmium term was significant (βCd = 0.0095, 95%CI: 0.0003, 0.0187). The term for
age was most responsible for reducing the urinary cadmium effect estimate (data not shown). Due to the convergence issue discussed in the methods this cofounding
assessment was made with urinary creatinine modeled
as a linear term. When urinary creatinine was modeled
as a linear term the effect estimate adjusted only for
creatinine (model 1) was: βCd = 0.0934 (95%CI: 0.0831,
0.1037) the multivariable-adjusted effect estimate
(model 2) was: βCd = 0.0082 (95%CI: -0.0014, 0.0178),
and the multivariable-adjusted effect estimate not
adjusted for age was: βCd = 0.0638 (95%CI: 0.0536,
0.0739).
Serial digit learning test (SDLT: learning recall/short-term
memory)

In the SDLT trials-to-criterion model adjusted only for
creatinine, the odds of a having a poor score increased
as urinary cadmium level increased (Table 3). In this
model, the Odds Ratio (OR) for having a poor (above
median) trials-to-criterion score associated with a 1 μg/L
increase in urinary cadmium was 1.50 (95%CI: 1.291.75). This association was no longer present after
multivariable-adjustment (ORCd = 1.03, 95%CI: 0.871.22) even when smoking status and cotinine were
removed from the model (ORCd = 0.98, 95%CI: 0.831.16). The age term was most responsible for reducing
the urinary cadmium effect estimate (data not shown).
When not adjusting for age the multivariable-adjusted
ORCd was 1.37 (95%CI: 1.15-1.63). The pattern of results
was similar in the SDLT total-error-score analysis
(Table 3, and when not adjusting for age the
multivariable-adjusted ORCd was 1.28, 95%CI: 1.08-1.52).

a

study population values, not weighted for oversampling.
b
urinary cadmium concentrations by quartiles of neurocognitive
test performance.

Sex interaction analyses

None of the sex-cadmium interaction terms were significant for any of the outcomes.
Cadmium associations within four age categories

Symbol digit substitution test (SDST: attention/
perception)

The effect estimate for urinary cadmium in the SDST
model adjusted only for creatinine was positive and significant (βCd = 0.0934, 95%CI: 0.0831, 0.1037) (Table 3).
Due to the log transformation of SDST score in these
models, this effect estimate predicts a 9.34% higher
SDST score with each 1 μg/L increase in urinary Cd
(again higher scores indicate worse performance). In the
multivariable-adjusted model the effect estimate was
reduced in magnitude and was no longer significant

Stratum specific effect estimates for urinary cadmium
within each of four age categories (20–29, 30–39, 40–49,
and 50–59 years) are presented in Table 4. In this analysis the multivariable effect estimate for SDST (attention/perception), which was not significant across the
full age spectrum, was larger in magnitude and significant in 3 of the 4 age categories.
Cadmium associations among never smokers with no
known occupational exposure

In analyses restricted to never smokers with no evidence
of work-based cadmium exposure (Table 5) the results
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Table 3 Associations between urinary cadmium concentration and neurocognitive test performance
SRTT

SDST

(visual motor speed)

(attention/perception)
% change in

% change in

score with a

score with a

1 μg/L increase

1 μg/L increase

N

βCda

in Cdb (95%CI)

N

βCda

in Cdb (95%CI)

Model 1

4833

0.0161*

1.61* (0.87, 2.35)

4998

0.0934*

9.34* (8.31, 10.37)

Model 2

4209

−0.0034

−0.34 (−1.22, 0.54)

4344

0.0068

0.68 (−0. 28, 1.64)

Model 3

4301

−0.0062

−0.62 (−1.45, 0.21)

4441

0.0095*

0.95* (0.03, 1.87)

SDLT
(learning recall/short-term memory)
SDLT trials-to-criterion
N

ORCd

Model 1

4826

Model 2
Model 3

c

SDLT total-error-score
c

(95%CI)

N

ORCd

1.50*

(1.29 - 1.75)

4889

1.48*

(95%CI)
(1.28 - 1.71)

4202

1.03

(0.87 - 1.22)

4253

0.97

(0.77 - 1.22)

4295

0.98

(0.83 - 1.16)

4348

0.97

(0.78 - 1.19)

Model 1. urinary cadmium and an independent term for urinary creatinine.
Model 2. add age, sex, race-ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other), smoking status (never, former, or current smoker),
serum cotinine, blood lead, language exam was given in (Spanish or English), education (in years), and poverty income ratio.
Model 3. same as model 2 but with smoking status and cotinine terms removed.
a
β for urinary cadmium (μg/L) with log transformed outcome.
b
percent change in test score associated with 1 μg/L increase in urinary cadmium (based on β). Note: higher scores correspond to worse performance.
c
OR for having a poor (above median) SDLT score associated with a 1 μg/L increase in urinary cadmium.
* significant at alpha = 0.05.

were roughly similar with two notable exceptions: 1) the
multivariable adjusted effect estimate in the SDST analysis (attention/perception) was larger in magnitude and
significant (βCd = 0.0193, 95%CI: 0.0005, 0.0381), and 2)
the multivariable adjusted effect estimate in the SDLT
total-error-score analysis (learning recall/short-term
memory) was larger in magnitude and borderline significant (ORCd = 1.45, 95%CI: 0.99 - 2.14).

Discussion
Interpretations

In this study of U.S. adults age 20–59 years, higher levels
of urinary cadmium were associated with worse performance on each of four neuropsychological tests when
the analyses were adjusted only for urinary creatinine.
These relationships were not significant after adjustment
for the full set of potential confounding variables (model
2). Adjustment for age in particular mitigated the effect
estimates for urinary cadmium. However, the relationship between higher urinary cadmium levels and poor
SDST scores was significant in the multivariableadjusted model that was not adjusted for smoking variables (model 3). Smoking is a source of cadmium exposure
[1] and smoking has been associated with neurocognitive
deficiencies [20]. Therefore cadmium may mediate some
of the effect of smoking on neurocognitive performance. If

so, including smoking variables in the models could underestimate the magnitude of associations with cadmium,
because cadmium-independent and cadmium-dependent
effects of smoking would be difficult to disentangle.
To further explore this issue we performed analyses
restricted to never smokers with no evidence of occupational cadmium exposure. These exclusions removed
potentially confounding co-exposures in tobacco smoke
and certain occupational environments from the analyses, thus allowing us to evaluate associations that
should be related primarily to dietary cadmium exposure
[1,20,31,32]. In these restricted analyses we found that
the association between higher urinary cadmium and
worse SDST score was still significant after multivariable
adjustment (βCd = 0.0193, 95%CI: 0.0005, 0.0381). Because the SDST assesses attention and perception, this
data suggests that elevated cadmium exposure in adults
may be associated with reduced capacity in these cognitive functions.
The effect estimate for urinary cadmium among never
smokers without occupational exposure (βCd = 0.0193)
predicts a 1.93% (95%CI: 0.05, 3.81) increase in SDST
score for a 1 μg/L increase in urinary cadmium. This
suggests that moving from the 25th to the 75th percentile of urinary cadmium (0.19 to 0.82 μg/L) would correspond to 1.22% increase in SDST score. Higher scores
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Table 4 Associations between urinary cadmium
concentration and neurocognitive test performance by
age category
SRTT

SDST

(visual motor speed)

(attention/perception)

% change in

% change in

score with a

score with a

1 μg/L increase

1 μg/L increase

βCda

in Cdb (95%CI)

βCda

in Cdb (95%CI)

20-29 yrs.

0.0132

1.32 (−1.02, 3.65)

0.0289*

2.89* (0.36, 5.42)

30-39 yrs.

−0.0059

−0.59 (−2.15, 0.97)

−0.0030

−0.30 (−2.02, 1.42)

40-49 yrs.

−0.0012

−0.12 (−1.33, 1.09)

0.0161*

1.61* (0.26, 2.95)

50-59 yrs.

−0.0046

−0.46 (−1.79, 0.88)

0.0196*

1.96* (0.46, 3.47)

SDLT
(learning recall/short-term memory)
SDLT trials-to-criterion

SDLT total-error-score

ORCd c

(95%CI)

ORCdc

(95%CI)

20-29 yrs.

0.89

(0.61, 1.30)

1.02

(0.66, 1.58)

30-39 yrs.

1.11

(0.74, 1.66)

0.96

(0.67, 1.37)

40-49 yrs.

1.21

(0.95, 1.55)

1.17

(0.91, 1.52)

50-59 yrs.

0.89

(0.70, 1.15)

0.83

(0.63, 1.08)

Model adjusted for urinary cadmium, urinary creatinine, sex, race-ethnicity
(non-Hispanic white, non-Hispanic black, Mexican American, and other),
smoking status (never, former, or current smoker), serum cotinine, blood lead,
language exam was given in (Spanish or English), education (in years), and
poverty income ratio.
a
β for urinary cadmium (μg/L) with log transformed outcome.
b
percent change in test score associated with 1 μg/L increase in urinary
cadmium (based on β). Note: higher scores correspond to worse performance.
c
OR for having a poor (above median) SDLT score associated with a 1 μg/L
increase in urinary cadmium.
* significant at alpha = 0.05.

indicate worse performance. While this effect size is
small in magnitude, low-level cadmium exposure is
nearly ubiquitous [10]. Thus if this association reflects a
causal relationship, there may be a public health impact
[33]. Furthermore, as we discuss below, this effect size
and it’s public health impact may be underestimated due
to the adjustment for age.
We also note here that the fully adjusted effect estimate for SDLT total error score was borderline significant when restricting to never smokers with no known
occupational cadmium exposure (ORCd = 1.45, 95%CI:
0.99 - 2.14). This provides evidence for a potential association with decreased performance in learning recall
and short-term memory as well.
For the 4 outcomes evaluated, adjusting for age produced the largest change in the urinary cadmium effect
estimates, and in each case, age adjustment resulted in a
decrease in the effect estimate. Because urinary cadmium concentration is a marker of cumulative exposure
it tends to increase with age (bivariate model with log

transformed urinary cadmium: βage = 0.0262, 95%CI:
0.0227, 0.0296). Cognitive performance on each of the
four tests decreased with age in our study population
and this is consistent with the findings of Kreig et. al. in
2001 [21] (bivariate models: SRTT βage = 0.0012 [95%CI:
0.0008, 0.0017]; SDST βage = 0.0097 [95%CI: 0.0091,
0.0102]; OR for having a poor [above median] SDLT
score associated with a 1 year increase in age: SDLT
trials-to-criterion: 1.04, 95%CI: 1.03-1.05, SDLT totalerror-score: 1.03, 95%CI: 1.02-1.04). The relationship
between age and urinary cadmium concentration makes
it difficult to determine if a portion of the age-associated
cognitive changes may be due to cumulative cadmium
exposure (i.e. cadmium may be on the causal pathway
between age and neurocognitive performance). For this
reason, adjusting for age may result in the underestimation of cadmium-test score associations. We nevertheless observed a significant association between urinary
cadmium concentration and SDST scores despite adjusting for age (in the analysis restricted to never smokers
with no known occupational exposure), and thus the
association could be larger in magnitude than reported
here. Though there is some instability in the urinary
cadmium effect estimates within age strata in the SDST
analysis (learning recall/short-term memory), these
results (Table 4) are consistent with interpretation that
adjusting for age may result in the underestimation of
the urinary cadmium-SDST association.
With respect to visual motor speed (SRTT) the age
interaction analysis is intriguing. Interestingly, a trend of
worse performance with higher urinary cadmium was
observed only in the youngest age group (20–29 years
of age), suggesting that age modifies the relationship
between cadmium and visual motor speed. The direction
of this effect estimate suggests that young adults may be
vulnerable to an adverse effect of cadmium on visual
motor speed, perhaps because their baseline performance speed is slightly faster than the older age groups.
None of the cadmium-sex interaction terms were significant, but future studies may still benefit from considering cadmium-sex interactions, in light of the evidence
that cadmium may mimic sex hormones, and have
different toxicokinetics in males and females [26].
Comparison to previous findings

As described in the introduction, there are a limited
number of epidemiologic studies which looked specifically for associations between cadmium exposure and
neurocognitive outcomes in adults. One study in Navy
recruits (n = 40) found that high hair cadmium levels
were significantly correlated with lower reading levels
and behavioral problems but the analysis did not consider potential confounding [2]. Another small study
(n = 31) evaluated occupationally exposed workers from
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Table 5 Associations between urinary cadmium concentration and neurocognitive test performance among never
smokers with no known occupational exposure
SRTT

SDST

(visual motor speed)

(attention/perception)
% change in

% change in

score with a

score with a

1 μg/L increase

1 μg/L increase

N

βCda

in Cdb (95%CI)

N

βCda

in Cdb (95%CI)

Model 1

2286

0.0299*

2.99* (1.39, 4.59)

2371

0.0922*

9.22* (6.99, 11.44)

Model 2

1986

−0.0088

−0.88 (−2.69, 0.93)

2050

0.0193*

1.93* (0.05, 3.81)

SDLT
(learning recall/short-term memory)
SDLT trials-to-criterion
N

ORCdc

SDLT total-error-score
(95%CI)

N

ORCdc

(95%CI)

Model 1

2270

1.70

(0.99 – 2.93)

2301

2.25*

(1.67 – 3.05)

Model 2

1967

1.12

(0.82 - 1.53)

1991

1.45

(0.99 – 2.14)

Model 1. urinary cadmium and an independent term for urinary creatinine.
Model 2. add age, sex, race-ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other), serum cotinine, blood lead, language exam was
given in (Spanish or English), education (in years), and poverty income ratio.
a
β for urinary cadmium (μg/L) with log transformed outcome.
b
percent change in test score associated with 1 μg/L increase in urinary cadmium (based on β). Note: higher scores correspond to worse performance.
c
OR for having a poor (above median) SDLT score associated with a 1 μg/L increase in urinary cadmium.
* significant at alpha = 0.05.

a refrigerator coil manufacturing plant and found that
workers with higher urinary cadmium levels had worse
performance in tests of attention/psychomotor speed,
and memory [4]. However, an alternate analysis found
no significant relationships between urinary cadmium
and performance after accounting for age and education.
In a study of 89 workers (42 exposed and 47 control),
urinary cadmium was significantly associated with poor
visuomotor performance (symbol digit substitution and
simple reaction time tests), even after adjusting for age,
alcohol, exposure to other neurotoxicants, neuroactive
medications, and years of schooling [3]. Case control studies suggest that elevated cadmium exposure or differences
in cadmium processing may be associated with violent
criminal behavior [34] and dementia/Alzheimer’s disease
[35,36], but the results have been inconsistent [37,38].
In addition to these small studies, three populationbased studies have been reported in elderly adults. One
of these studies involved the evaluation of trace minerals
in drinking water and dementia/cognitive screening of
elderly people in China (n =1,016) [5]. This study did
not detect an association between cognitive score and
water cadmium levels but did identify a significant zinccadmium interaction. Participants with high levels of both
zinc and cadmium in their water had lower cognitive
scores. This group published another population-based
study of elderly people in China that evaluated metal biomarkers in blood plasma rather than in drinking water

(base study population: n = 2000, blood sample subpopulation: n = 188) [6]. Here the authors reported an
association between higher plasma cadmium levels and
lower composite cognitive scores after adjusting for
age, gender, education, APOE genotype and BMI. A
third study of elderly people was conducted in Stockholm (study population: n = 804, subsample analyzed
for blood cadmium: n = 763) [7]. In this study no association was found between blood cadmium and minimental status exam (MMSE) scores, but in this report
the composition of their regression models is unclear,
and thus it is difficult to assess how potential confounding was addressed.
The previous work most comparable to our own in
terms of outcomes measures (NES computerized neurobehavioral testing) is the study by Viaene et al [3]. The
primary difference in the Viene et. al. study is that it was
done in an occupational study population with higher
exposure levels. In this work the authors found significant relationships between urinary cadmium and poor
performance in both a simple reaction time test (visual
motor speed) and a symbol digit substitution test (attention and perception). The results of our unadjusted SRTT
analyses were consistent with their findings, although we
did not detect a significant association between urinary
cadmium and SRTT after multivariable adjustment. We
found a similar relationship between urinary cadmium
and SDST scores, and this association was significant
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when we made our models more similar to those of
Viaene et al., by not adjusting for smoking. In our study
this relationship with SDST was also significant in the
subpopulation of never smokers with no known occupational cadmium exposure. Our study primarily involved
low-level non-occupational cadmium exposures, and we
controlled for different (as well as more) potential confounding variables. These factors may explain the differences in the findings of the studies.
The other study which assessed similar neurocognitive
testing outcomes (Hart et. al 1989) involved the evaluation
of 31 occupationally exposed workers, and the authors
reported decreased attention, psychomotor speed, and
memory in workers with higher urinary cadmium levels
[4]. Though these associations were no longer significant
after adjusting for age and education, the similarity of
identified domains is worth noting.
The exposure metrics, exposure sources, exposure levels,
sample sizes, age of participants, ethnicity of participants,
outcome metrics, and consideration of potential confounders vary greatly among the prior epidemiologic studies.
Despite these differences, 3 of the 4 large population-based
studies, including our own, provide evidence linking cadmium exposure to worse neurocognitive performance in
adults [5-7]. Additionally, the studies which attempted to
evaluate neurocognitive domains, including our own, have
identified similar domains: attention/perception (and perhaps memory) [3,4]. Furthermore, there is evidence that
cadmium exposure may be associated with adverse neurodevelopmental outcomes in children (briefly reviewed in [39]).
With respect to possible mechanisms, laboratory animal
experiments have demonstrated that cadmium exposure
can affect neurotransmitter function, electrophysiological
parameters, and behavior [40-47]. Combined with the
epidemiologic studies, these reports from experimental
toxicology increase the public health concerns about
cadmium exposure and neurocognition.
Implications for cadmium risk assessments

Recent risk assessments have established urinary cadmium reference levels to protect against kidney damage
(EFSA 2009: 1 μg Cd/g creatinine, WHO/FAO 2011:
5.24 μg Cd/g creatinine), as this has been considered the
most sensitive endpoint of cadmium toxicity [1,10]. In
our study we did not use creatinine-standardized urinary
cadmium to assess exposure. We instead included urinary creatinine as an independent term in our regression
models as recommended by Barr et al. 2005 [19], but we
can compare our results to these reference levels by
evaluating our models within the exposure ranges
defined by these reference levels. We added a reference
level-cadmium interaction term to our fully adjusted
SDST models and extrapolated stratum specific effect
estimates for urinary cadmium among participants with
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1) less 1 μg Cd/g creatinine, 2) 1–5.24 μg Cd/g creatinine, and 3) greater than 5.24 μg Cd/g creatinine. Excluding the extreme outlier there were only 2 participants
with urinary cadmium levels above 5.24 μg Cd/g creatinine in the full study population, and among the never
smokers with no known occupational cadmium exposure there were no urinary cadmium concentrations
above this level, thus the highest exposure category
could not be evaluated in these analyses.
In the general study population we found evidence
that the inverse relationship between urinary cadmium
concentration and SDST performance may be present
among those with 1–5.24 μg Cd/g creatinine (βCd =
0.0114, 95%CI: -0.0016, 0.0244) but not present among
those with less 1 μg Cd/g creatinine (βCd = −0.0133, 95%
CI: -0.0298, 0.0031). Among the never smokers with no
known occupational cadmium exposure we saw a similar
pattern, however the association magnitude was much
greater and highly significant among those with 1–5.24 μg
Cd/g creatinine (1–5.24 μg Cd/g creatinine: βCd = 0.0510,
95%CI: 0.0217, 0.0804, less than 1 μg Cd/g creatinine:
βCd = −0.0223, 95%CI: -0.0509, 0.0064). If this relationship reflects a casual mechanism then our data suggests that neurocognitive performance may be a sensitive
endpoint of cadmium toxicity in adults and that the
WHO/FAO reference level may not protect against
this effect.
Recent evidence suggests that decreased rates of smoking are contributing to decreases in cadmium exposure
in the U.S [48]. However, our study suggests that nonsmoke, non-occupation based cadmium exposure may
be associated with adverse neurocognitive outcomes in
adults at levels below 5.24 μg Cd/g creatinine (the
current WHO/FAO reference level). If this association
reflects a causal relationship then common low level dietary cadmium exposures may be responsible decreased
neurocognitive function in many U.S. adults. Further neurocognitive research should be conducted and new risk
assessments for cadmium may be needed. It is important
to note that associations with adverse neurodevelopmental
outcomes in children have been recently been reported at
cadmium levels below 1 μg Cd/g creatinine [39] and
therefore the findings in children may have a larger impact
on future risk assessments.
Limitations and strengths

Our study is limited by the cross-sectional nature of the
data, which restricts our ability to assess the temporal
relationships between variables. However the long half-life
of cadmium in the body (> 10 years) and the cumulative
nature of the urinary cadmium exposure metric [16] suggest that at least some component of the exposure measurement reflects cadmium exposure which occurred well
before the neurocognitive outcome measurement. We also

Ciesielski et al. Environmental Health 2013, 12:13
http://www.ehjournal.net/content/12/1/13

note that our findings, like those of any observational
study, may reflect non-causal relationships related to
uncontrolled confounding.
The main strengths of our analysis include: a large sample size, adjustment for multiple potential confounders,
sufficient information on exposure routes to evaluate nonsmoking nonoccupational cadmium exposure, and the use
of an objective computer-based neuropsychological evaluation that was designed for epidemiologic applications [9].
Additional strengths of our analysis include use of penalized splines to assess and account for nonlinear relationships, as well as the use of a dataset that was designed to
be representative of the U.S. population.

Conclusions
Overall, these results provide support for the evidence
suggesting that cadmium exposure may be associated with
diminished neurocognitive performance in adults. The
relationships observed in this study were detected at cadmium exposure levels that are 1) typical of US adults and
2) below the current WHO/FAO reference level. The
associations between urinary cadmium and neurocognitive outcomes prior to multivariable-adjustment may be
due in part to confounding by age. However the
multivariable-adjusted models and age stratified analyses
indicate that confounding by age does not completely
explain the relationship between urinary cadmium and
SDST scores, a measure of attention and perception. Confounding by co-exposures in tobacco smoke and occupational environments also cannot explain this association,
as this relationship was significant among never smokers
with no known work based cadmium exposure (dietary
cadmium is the primary source of exposure in this subpopulation). These findings combined with evidence from
laboratory experiments and prior epidemiologic studies
highlight the need for population based prospective studies to evaluate the potential neurotoxic effects of cadmium
exposure.
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